PRECIGEN Investors


Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Nov 12, 2021

A trial-in-progress update on the PRGN-2009 study titled, “Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers,” was presented as a poster presentation (#483) by Charalampos S. Floudas, MD, DMSc, MS, Assistant Research Physician, Genitourinary Malignancies Branch at the Center for Cancer Research at the National Cancer Institute (NCI).